Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1067 | 1044 | 1155 | 1248 | 1598 | 2913 |
Fund Return | 6.72% | 4.4% | 15.5% | 7.66% | 9.83% | 11.29% |
Place in category | 4035 | 3750 | 4144 | 2036 | 1440 | 448 |
% in Category | 59 | 55 | 67 | 41 | 38 | 21 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Capital Group New Perspective Fuzgg | 13.94B | 4.28 | 1.56 | 9.84 | ||
Capital Group New Perspective Fubg | 13.94B | 4.01 | 0.79 | 8.96 | ||
Capital Group New Perspective Fubdg | 13.94B | 4.00 | 0.79 | 8.95 | ||
Capital Group New Perspective Funbg | 13.94B | 4.06 | 0.81 | 8.96 | ||
Capital Group New Perspective Funzg | 13.94B | 4.30 | 1.56 | 9.83 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
MS Global Brands Fund AXg | 21.41B | -0.58 | 2.17 | 8.35 | ||
MS Global Brands Fund Zg | 21.41B | -0.24 | 3.10 | 9.22 | ||
Investment Funds Global Brands Funz | 21.41B | -0.24 | 3.10 | 9.22 | ||
Developed World Index Sub Fund FleA | 22.14B | 6.67 | 9.37 | 12.31 | ||
Developed World Index Sub Fund Flex | 22.14B | 6.67 | 9.12 | 12.20 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 3.23 | 927.3 | +1.13% | |
Broadcom | US11135F1012 | 2.79 | 1,328.55 | -2.45% | |
Microsoft | US5949181045 | 2.33 | 415.13 | +0.23% | |
Safran | FR0000073272 | 2.07 | 214.10 | +0.14% | |
AstraZeneca | GB0009895292 | 2.05 | 12,190.0 | +1.35% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Sell | Strong Buy | Strong Buy |
Summary | Neutral | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review